Search research articles
Contact Us
Filters
Showing results (61-70 of 638) with videos related to
Page
of 64
Sort By:
Anti-Cancer Drugs
|
April 7, 2007
ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer
Haiqing Li, Douglas K Price, William D Figg
Cancer Biology & Therapy
|
May 6, 2016
YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?
Fiorina Kyritsi, Douglas K Price, William D Figg
Translational Cancer Research
|
February 27, 2024
How far does a new horizon extend for rucaparib in metastatic prostate cancer?
Fatima Karzai, Ravi A Madan, William D Figg
Cancer Biology & Therapy
|
June 12, 2014
Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy
Shandiz Shahbazi, Cody J Peer, William D Figg
Cancer Biology & Therapy
|
November 15, 2002
Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel
Mikhail V Blagosklonny, Zbigniew Darzynkiewicz, William D Figg
Pharmacotherapy
|
June 18, 2002
Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
Michelle A Rudek, Jürgen Venitz, William D Figg
Cancer Biology & Therapy
|
June 10, 2015
Evaluating immune responses after sipuleucel-T therapy
Julius Strauss, Ravi A Madan, William D Figg
Expert Opinion on Drug Metabolism & Toxicology
|
July 26, 2006
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination
Nicola F Smith, William D Figg, Alex Sparreboom
Current Oncology Reports
|
April 26, 2005
Angiogenesis and prostate cancer: important laboratory and clinical findings
Michael C Cox, Matthew Permenter, William D Figg
Journal of Oncology Practice
|
September 23, 2010
Even more cost savings?
James L Gulley, William D Figg, William Dahut
Page
of 64
Search research articles
Search
Showing results (61-70 of 638) with videos related to
Sort By:
Page
of 64
Anti-Cancer Drugs
|
April 7, 2007
ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer
Haiqing Li, Douglas K Price, William D Figg
Cancer Biology & Therapy
|
May 6, 2016
YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?
Fiorina Kyritsi, Douglas K Price, William D Figg
Translational Cancer Research
|
February 27, 2024
How far does a new horizon extend for rucaparib in metastatic prostate cancer?
Fatima Karzai, Ravi A Madan, William D Figg
Cancer Biology & Therapy
|
June 12, 2014
Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy
Shandiz Shahbazi, Cody J Peer, William D Figg
Cancer Biology & Therapy
|
November 15, 2002
Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel
Mikhail V Blagosklonny, Zbigniew Darzynkiewicz, William D Figg
Pharmacotherapy
|
June 18, 2002
Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
Michelle A Rudek, Jürgen Venitz, William D Figg
Cancer Biology & Therapy
|
June 10, 2015
Evaluating immune responses after sipuleucel-T therapy
Julius Strauss, Ravi A Madan, William D Figg
Expert Opinion on Drug Metabolism & Toxicology
|
July 26, 2006
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination
Nicola F Smith, William D Figg, Alex Sparreboom
Current Oncology Reports
|
April 26, 2005
Angiogenesis and prostate cancer: important laboratory and clinical findings
Michael C Cox, Matthew Permenter, William D Figg
Journal of Oncology Practice
|
September 23, 2010
Even more cost savings?
James L Gulley, William D Figg, William Dahut
Page
of 64